注射用生物製药市场 - 技术，治疗，市场，策略，预测

Injectable Biological Drugs - Technologies, Therapeutics, Markets, Strategies & Forecasts

出版日期: 2025年01月30日 | 出版商:

Greystone Research Associates | 英文 128 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

按药物类别划分，生物製剂在开发和临床试验中继续超过所有其他新化学实体。由于生物製剂通常针对慢性病，因此必须制定剂量策略和治疗方案以承受长期使用，并且通常由可能受到与其医疗状况直接相关的限制的患者自行开发。抗体、荷尔蒙、酵素和其他生物製剂的强大生理效应也推动了对安全性和依从性的需求。设备设计人员和药物开发人员之间的合作发生在药物开发週期的早期，通常允许设备设计以匹配特定药物治疗的生物利用度目标和药物动力学特征。目前正在开发的新型注射输送装置设计可能为替代注射方法创造新的机会。设备供应商和製药公司之间的合作有望加速市场对许多新兴疗法的新型注射设备的接受，包括治疗性疫苗、基于 DNA 的药物和蛋白质衍生的生物製剂。

报告价值矩阵

本报告提供注射用生物製药市场相关调查，彙整市场概要，以及患者的未满足需求等的市场机会，生技药品的药物输送的课题与限制，各类药物的产品分析，及的加入此市场的主要企业的简介等资讯。

"Injectable Biological Drugs: Technologies, Therapeutics, Markets, Strategies and Forecasts" is a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind this evolving segment of the healthcare sector. The study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, disease segments, and commercial opportunities for injection devices for administering biologicals. Provider organization business managers, healthcare administrators and investors will also benefit from this study.

New Platforms for Biological Drug Delivery

Biological drugs as a class continue to outpace all other NCEs in development pipelines and clinical trials. Because biological drugs most often target chronic conditions, dosing strategies and treatment protocols must be developed for long-term use, often for self-administration by patients who may have limitations directly related to their condition. The powerful physiological effects of antibodies, hormones, enzymes and other biological drugs also increase the need for safety and adherence. Cooperation between device designers and drug developers is occurring much earlier in the drug development cycle, allowing device designs in many cases to be tailored to the bioavailability targets and pharmacokinetic profiles of specific drug therapies. New injectable delivery device designs currently being developed will create new opportunities for alternative injection methods. Partnerships between device suppliers and pharmaceutical companies will foster market acceptance of new injection devices for a host of new therapies such as therapeutic vaccines, DNA-based drugs, and protein-derived biologics.

Report Value Matrix

What You Will Learn:

What are the product and user requirements that drive the biological drug-device selection process?
What are the essential design factors, technologies and market development issues for injection devices capable of administering biological dugs?
What is the impact of development-stage biological manufacturing process changes on device go-to-market readiness and how has it changed in recent years?
How do device selection decisions align across biological drug classes? Therapeutic targets? Market segments?
What is the impact of drug-device dependencies on pre- and post-marketing product life cycle management?
What are the significant economic, technology, and regulatory factors affecting the market for biological drug injection devices?